Consumers more loyal to Tylenol brand
PHILADELPHIA According to a study released by the Relational Capital Group, despite product recalls and a plant closure, consumer purchase intent and brand loyalty for Tylenol still currently exceeds that of Advil.
According to the study, conducted by Princeton University professors Susan Fiske and Nicolas Kervyn, 76% of consumers reported positive purchase intent and 67% reported positive brand loyalty for Tylenol, compared with 75% and 65% for Advil, respectively. In addition, Tylenol matched or surpassed Advil on most warmth and competence dimensions, including “acts with your best interests in mind.” Warmth and competence dimensions are both indicators of brand loyalty.
“This suggests that despite how painful the product recalls and plant closure have been for [McNeil Consumer], it appears their efforts thus far have been effective in retaining consumer trust and brand loyalty,” stated Chris Malone, chief advisory officer of The Relational Capital Group.
Conducted July 1 to 7, this study measured the warmth and competence perceptions and priorities of a demographically balanced sample of 1,042 U.S. adult consumers for eight national brands, as well as their purchase intent and brand loyalty toward each. The brands examined included McDonalds, Burger King, BP, Shell, Tropicana, Minute Maid, Tylenol and Advil.
Everlast Sports Nutrition launches ProLine collection
NEW YORK Everlast Sports Nutrition on Thursday announced the launch of its ProLine collection, a sports nutrition line of products for pre- and post-workout.
Developed by a team of industry professionals to include nutritionists, athletes and fitness-enthusiasts, ProLine was created to deliver scientifically validated ingredients in proven cutting-edge sports nutrition products for optimum athletic performance, the company stated.
“We’re proud to offer the first comprehensive line of nutritional supplements worthy of the Everlast name,” stated Everlast Sports Nutrition CEO Peter Brechter. “The ProLine rounds out our portfolio, and now we truly have something for everyone.”
The ProLine assortment includes:
- N.O. Nitro-Plex — formulated to support and enhance maximum vascularity, strength, power and endurance. Suggested retail price is $64.99;
- NitroPlex-6 — Designed to effectively increase blood flow, oxygen support and the delivery of nutrients to skeletal muscle. SRP $59.99;
- HyperPlex protein bars — A triple-layered bar with 30 g of protein, designed to support healthy muscle recovery and energy. Available in three flavors: butternut crunch, chocolate caramel nougat and fudge cookie crunch. SRP $2.99;
- HyperPlex protein powder — A protein powder with a multiblend of 25 g of high protein for improved muscle definition. The poweder contains Plyosyl for enhanced muscle and joint health, and improved elasticity and firmness. SRP $44.99;
- HyperPlex ready to drink shake — A protein drink with 40 g of both slow- and fast-acting proteins for muscle recovery and growth. SRP $3.99; and
- Thermo Triplex — A weight-loss supplement combining an appetite suppressant with thermogenic compounds. SRP $64.99.
J&J CEO announces organizational changes
NEW YORK In an interview with the Wall Street Journal on Wednesday, Johnson & Johnson chairman and CEO William Weldon outlined a number of organizational changes taking place across the company in light of the recent spate of recalled products at McNeil Consumer Healthcare, a J&J company.
First, there is the creation of a corporate oversight group, headed by Ajit Shetty, who will be in charge of operations for the company’s pharmaceuticals, medical device and consumer segments. Shetty will report directly to Weldon.
Each of J&J’s business units will field its own chief quality officer, all of whom will report to Shetty. Managers of J&J’s 120 manufacturing facilities worldwide likewise will report to Shetty.
“The people who use our products are our first priority, and we’ve let them down,” Weldon told the Wall Street Journal, adding that the company has “a lot to do to earn [trust in the company] back.”
Weldon also vowed to regain the confidence of retailers impacted by the McNeil recalls over the course of 2011, once production of those recalled medicines resumes. J&J currently is refitting its Fort Washington, Pa., plant and is planning to invest in the upgrade of other McNeil facilities as well. Production at the Fort Washington plant isn’t expected to resume until the second half of 2011. However, McNeil has parlayed production of the recalled products across other sites, and expected to have supply for those products by first quarter 2011, according to previous reports.